193 related articles for article (PubMed ID: 25286037)
1. Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
van Vugt VA; Piccioni DE; Brown BD; Brown T; Saria MG; Juarez T; Kesari S
CNS Oncol; 2014 Jul; 3(4):257-65. PubMed ID: 25286037
[TBL] [Abstract][Full Text] [Related]
2. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
[TBL] [Abstract][Full Text] [Related]
4. Extended-schedule dose-dense temozolomide in refractory gliomas.
Berrocal A; Perez Segura P; Gil M; Balaña C; Garcia Lopez J; Yaya R; Rodríguez J; Reynes G; Gallego O; Iglesias L;
J Neurooncol; 2010 Feb; 96(3):417-22. PubMed ID: 19669096
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
Abacioglu U; Caglar HB; Yumuk PF; Akgun Z; Atasoy BM; Sengoz M
J Neurooncol; 2011 Jul; 103(3):585-93. PubMed ID: 20878446
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Minniti G; Scaringi C; De Sanctis V; Lanzetta G; Falco T; Di Stefano D; Esposito V; Enrici RM
J Neurooncol; 2013 Jan; 111(2):187-94. PubMed ID: 23129347
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Kim YH; Park CK; Cho WH; Kim IA; Moon S; Choe G; Park SH; Kim IH; Kim DG; Jung HW; Lee MM; Bae SH; Cha SH; Kim CY
J Neurooncol; 2011 Jul; 103(3):503-12. PubMed ID: 20862518
[TBL] [Abstract][Full Text] [Related]
8. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Han SJ; Rolston JD; Molinaro AM; Clarke JL; Prados MD; Chang SM; Berger MS; DeSilva A; Butowski NA
Neuro Oncol; 2014 Sep; 16(9):1255-62. PubMed ID: 24670608
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Omuro A; Chan TA; Abrey LE; Khasraw M; Reiner AS; Kaley TJ; Deangelis LM; Lassman AB; Nolan CP; Gavrilovic IT; Hormigo A; Salvant C; Heguy A; Kaufman A; Huse JT; Panageas KS; Hottinger AF; Mellinghoff I
Neuro Oncol; 2013 Feb; 15(2):242-50. PubMed ID: 23243055
[TBL] [Abstract][Full Text] [Related]
11. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Kocher M; Kunze S; Eich HT; Semrau R; Müller RP
Strahlenther Onkol; 2005 Mar; 181(3):157-63. PubMed ID: 15756519
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Wei W; Chen X; Ma X; Wang D; Guo Z
J Neurooncol; 2015 Nov; 125(2):339-49. PubMed ID: 26334318
[TBL] [Abstract][Full Text] [Related]
16. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas.
Yaman E; Buyukberber S; Uner A; Coskun U; Yamac D; Ozturk B; Kaya AO; Yildiz R; Benekli M;
Tumori; 2008; 94(5):674-80. PubMed ID: 19112939
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W
J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide in the treatment of recurrent malignant glioma.
Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]